Blog | Medicare Payment and Reimbursement

Update on Medicare payment policy for treatments involving bamlanivimab

Blog | Medicare Payment and Reimbursement

Update on Medicare payment policy for treatments involving bamlanivimab

Medicare no longer will pay healthcare providers for administering the COVID-19 treatment bamlanivimab now that the FDA has revoked the Emergency Use Authorization for treatments in which the drug is administered alone.

Medicare will cover and pay for bamlanivimab, when administered alone, only for dates of service from Nov. 10, 2020 through April 16, 2021.

The FDA wrote that it has "has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use."

In a letter to Eli Lilly, the manufacturer of bamlanivimab, Denise Hinton, FDA chief scientist, cited the increasing prevalence of variants of the novel coronavirus and the risk that these variants are resistant to bamlanivimab as a sole treatment.

The FDA indicates that other monoclonal antibody therapies remain appropriate to treat COVID-19 patients, and providers may continue using the following authorized therapies when administered together:

  • Casirivimab and imdevimab
  • Bamlanivimab and etesevimab

“While the risk-benefit assessment for using bamlanivimab alone is no longer favorable due to the increased frequency of resistant variants, other monoclonal antibody therapies authorized for emergency use remain appropriate treatment choices when used in accordance with the authorized labeling and can help keep high-risk patients with COVID-19 out of the hospital,” Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, said in a release.

“We urge the American public to seek out these therapies when needed while we continue to use the best data available to provide patients with safe and effective treatments during this pandemic.”

About the Author

Nick Hut

is a senior editor with HFMA, Westchester, Ill. (nhut@hfma.org).

Sign up for a free guest account and get access to five free articles every month.

Advertisements

Related Articles | Medicare Payment and Reimbursement

News | Cost Effectiveness of Health

The stakes are only growing in efforts to improve the cost effectiveness of health, CMMI’s Elizabeth Fowler says

The head of the Center for Medicare & Medicaid Innovation spoke with an HFMA audience about the importance of efforts at the federal level and beyond to improve the cost effectiveness of health.

Blog | Coronavirus

Recipients of COVID-19 vaccine boosters won’t have to pay anything out of pocket, CMS confirms

Medicare beneficiaries will owe nothing out of pocket for receiving an authorized booster dose, and the same applies to almost all Medicaid beneficiaries and most commercial health plan members.

How To | Cost Effectiveness of Health

Why responding to site-neutral payment risk is imperative for hospitals and health systems

As the likelihood of site-neutral payments increases over a range of services, hospitals and health systems must understand which services are most at risk from these changes and determine how quickly they will respond.

News | Cost of Care

Site-of-care payment issues get highlighted by UnitedHealthcare and MedPAC

A new report issued by a leading health plan is the latest sign that hospitals and health systems can expect payers to ramp up implementation of site-neutral payments.